Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

doi:10.1182/bloodadvances.2020004173

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

Blood advances - 27 Apr 2021

Lachowiez Curtis A, Loghavi Sanam, Furudate Ken, Montalban-Bravo Guillermo, Maiti Abhishek, Kadia Tapan, Daver Naval, Borthakur Gautam, Pemmaraju Naveen, Sasaki Koji, Alvarado Yesid, Yilmaz Musa, Short Nicholas J, Chien Kelly, Ohanian Maro, Pierce Sherry, Patel Keyur P, Jabbour Elias, Ravandi Farhad, Kantarjian Hagop M, Garcia-Manero Guillermo, Takahashi Koichi, Konopleva Marina Y, DiNardo Courtney D

Abstract excerpt

Spliceosome mutations (SRSF2, SF3B1, U2AF1, ZRSR2), are encountered in ∼50% of secondary acute myeloid leukemia cases (sAML) and define a molecular subgroup with outcomes similar to sAML in de novo AML patients treated with intensive chemotherapy. Outcomes in patients with spliceosome mutations treated with hypomethylating agents in combination with venetoclax (HMA+VEN) remains unknown. The primary objective was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nuclear Proteins

Share to Serine-Arginine Splicing Factors

Share to Splicing Factor U2AF

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 33885753
DOI: 10.1182/bloodadvances.2020004173
PMCID: PMC8095152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.PMID 33885753Read ↗

Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.Semantic proximity Read ↗

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.Semantic proximity Read ↗

Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.Semantic proximity Read ↗

Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.Semantic proximity Read ↗

Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical FeaturesSemantic proximity Read ↗

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.Semantic proximity Read ↗

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.Semantic proximity Read ↗

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese PatientsSemantic proximity Read ↗

SRSF2 mutations drive daunorubicin resistance in acute myeloid leukemia via THBS1 stabilization.Semantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Complex landscape of alternative splicing in myeloid neoplasms.Semantic proximity Read ↗

Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.